Evidence map›Paper›PMID 37253762›Full record

ArticleScientific reports2023

Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor.

Gokulnath Mahalingam, Porkizhi Arjunan, Yogapriya Periyasami, Ajay Kumar Dhyani, Nivedita Devaraju, Vignesh Rajendiran, Abisha Crystal Christopher, Ramya Devi Kt, Immanuel Dhanasingh, Saravanabhavan Thangavel and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Gokulnath MahalingamCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Porkizhi ArjunanCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Yogapriya PeriyasamiCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Ajay Kumar DhyaniCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Nivedita DevarajuCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Vignesh RajendiranCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Abisha Crystal ChristopherCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Ramya Devi KtDepartment of Biotechnology, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India.
Immanuel DhanasinghCentre for Bio-Separation Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
Saravanabhavan ThangavelCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Mohankumar MurugesanCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Mahesh MoorthyDepartment of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India.
Alok SrivastavaCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India.
Srujan MarepallyCentre for Stem Cell Research (CSCR) (a Unit of inStem, Bengaluru), CMC Campus, Vellore, Tamil Nadu, 632002, India. srujankm@cmcvellore.ac.in.
Institute for Stem Cell Biology and Regenerative Medicine · INChristian Medical College & Hospital · INSRM Institute of Science and Technology · INVellore Institute of Technology University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spike glycoprotein of SARS-CoV-2 variants plays a critical role in infection and transmission through its interaction with human angiotensin converting enzyme 2 (hACE2) receptors. Prior findings using molecular docking and biomolecular studies reported varied findings on the difference in the interactions among the spike variants with the hACE2 receptors. Hence, it is a prerequisite to understand these interactions in a more precise manner. To this end, firstly, we performed ELISA with trimeric spike glycoproteins of SARS-CoV-2 variants including Wuhan Hu-1(Wild), Delta, C.1.2 and Omicron. Further, to study the interactions in a more specific manner by mimicking the natural infection, we developed hACE2 receptors expressing HEK-293T cell line, evaluated their binding efficiencies and competitive binding of spike variants with D614G spike pseudotyped virus. In line with the existing findings, we observed that Omicron had higher binding efficiency compared to Delta in both ELISA and Cellular models. Intriguingly, we found that cellular models could differentiate the subtle differences between the closely related C.1.2 and Delta in their binding to hACE2 receptors. Our study using the cellular model provides a precise method to evaluate the binding interactions between spike sub-lineages to hACE2 receptors.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2HumansMolecular Docking SimulationProtein BindingSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID37253762
PMCPMC10227802
OpenAlexW4378781326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.